1236-P: Patients with Diabetes Mellitus and Chronic Kidney Disease Affected by Nonalcoholic Fatty Liver Disease Have Greater Risk of Mortality and Worse Clinical Outcomes

Abstract

Background: DM & CKD are affecting million patients worldwide. Nonalcoholic Fatty Liver Disease (NAFLD) is emerging disease predisposing to adverse outcomes. There is limited evidence of clinical outcomes of NAFLD in patients with DM&CKD. We sought to investigate this population. Methods: We queried NIS 2017-2020 for adults hospitalized with DM&CKD & NAFLD. The primary outcome was inpatient mortality. The secondary outcomes were cardiogenic shock, cardiac arrest, GIB, intubation, LOS & total hospital charge. Multivariable logistic regression analysis was used to estimate clinical outcomes. Results: There were 11,254,722 hospitalizations with DM&CKD and 542,140 (4.8%) had NAFLD. NAFLD & non-NAFLD cohorts were with mean age of 53.3 vs. 54.0 yrs; males 53.3% vs 54.0%; Caucasians 58.7% vs 57.7%; HF 49.4% vs 49.5%; PH 11.4% vs 9.0%; AKI 51.9% vs 43.7%; obesity 24.9% vs 27.0%; HLD 47.0% vs 61.1%; anemia 23.6% vs 20.1%; ACS 10.6% vs 10.3%; stroke 1.8% vs 3.0%, respectively. Conclusion: DM&CKD cohort showed significantly higher mortality, worse clinical outcomes & resource utilization (Table 1). They were younger, obese, female, Caucasian, & with more PH, AKI, anemia, ACS. NAFLD is associated with greater risk for MACE, GIB, & ICU care. NALFD is an important risk factor among patients with DM&CKD that predicts adverse outcomes. Disclosure L. Khokhlov: None. U. Thapa: None. L. Pereira: None. M. Fatuyi: None. M. Ali: None. F. Hussain: None. A. Aboelnasr: None. A.C. Brown: None. M. Eerhart: None. M. Eshghabadi: None. C. Contreras: None. K. Shemisa: Speaker's Bureau; Pfizer Inc., Boehringer Ingelheim (Canada) Ltd., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Amarin Corporation, Bayer Inc.